56ACTIVITIES
1ORGS REPRESENTED
65BILLS
Organizations represented
1Orgs whose LD-2 filings list Zach as an active lobbyist, sorted by activity volume.
Bills they file on
65S. 265824 mentions
S. 229624 mentions
S. 4314 mentions
S. 70814 mentions
S. 104014 mentions
S. 104114 mentions
S. 109514 mentions
S. 109614 mentions
S. 109714 mentions
H.R. 89014 mentions
H.R. 157414 mentions
S. 65214 mentions
S. 83214 mentions
S. 89114 mentions
S. 93214 mentions
+ 50 more bills referenced in their activities
Topics in Filings
86Policy topics Zach files on across all their LD-2 activities.
RESTORE Patent Rights Act×28
Supply chain policy×28
One Big Beautiful Bill Act×26
Big Savings Act×25
Inflation Reduction Act×25
Drug cost and pricing policy×25
Biopharmaceutical innovation policy×25
BIOSECURE Act×24
Most Favored Nation×24
Skinny Labels×14
Affordable Prescriptions for Patients Act×14
Stop STALLING Act×14
Show all 86 topics (+74 more) ▾
Preserve Access to Affordable Generics and Biosimilars Act×14
Interagency Patent Coordination and Improvement Act×14
Bayh-Dole march-in rights policy×14
Patent thicket policy×14
AI patent policy×14
Patent eligibility policy×14
Post-grant proceeding policy×14
Patent submission policy×14
Modernizing and Ensuring PBM Accountability×14
Accountability, and Integrity Now and for the Future×14
Vaccine policy×14
Pharmacy Benefit Manager reform×14
Drug importation policy×14
FDA policy×14
Orphan Drug Act×14
Compounding policy×14
Clinical trial policy×14
Issues 340B drug discount program policy×14
Biosimilar approval and reimbursement policy×14
Artificial intelligence policy×14
International intellectual property and market access policy×14
Pricing and reimbursement policy×14
WTO TRIPS waiver policy×14
China outbound investment policy×14
FDA Modernization×14
Medication Affordability and Patent Integrity Act×13
Biosimilar Red Tape Elimination Act×13
Stopping Pharmas Ripoffs and Drug Savings For All Act×12
Bipartisan Health Care Act×12
IRA price negotiation expansion policy×12
MAHA Commission Report×12
Make Our Children Healthy Again Competition policy×12
Issues 340B rebate pilot program Patient assistance program policy×12
Biosimilars Access and Affordability Act×12
Patent fee policy×11
PBM Price Transparency and Accountability Act×11
Mikaela Naylon Give Kids a Chance Act×11
PBM Reform×11
HELP Copays Act×11
Antimicrobial resistance policy×11
Part D redesign and policy×11
Part B policy×11
Medicare rebate policy×11
Center for Medicare and Medicaid Innovation×11
Medicaid rebate policy×11
GENErating cost Reductions for U.S×11
Medicare Against Rising Drugs Costs×11
US-UK Framework Agreement×11
CLEAR LABELS Act×10
Most Favored Patients Act×10
FAIR ACT×10
SECURE Rx Act×10
Rural Development×6
User fee issues×4
Patent use codes policy×3
Give Kids a Chance Act×3
Antimicrobial resistance×3
Science, and Related Agencies Appropriations Act, 2026×3
Accelerated approval policy×2
Competition policy×2
Patient assistance program policy×2
Drug shortages policy×2
Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H×2
Res. 566: Providing for consideration of the Senate amendment to the bill×2
Protecting Patients from Deceptive Drug Ads Act×1
Innovation in Pediatric Drugs Act×1
Pandemic preparedness policy×1
Tariff policy×1
Military Construction×1
Expedited Acccess to Biosimilars Act×1
MAPS Act×1
Orphan Cures Act×1
Prescription Information Modernization×1
Open Payments Expansion Act×1
Issue mix
LDA general-issue codes weighted by activity count.
Copyright/Patent/Trademark14
Health Issues14
Trade (domestic/foreign)14
Medicare/Medicaid11
Budget/Appropriations3